Growth inhibition and differentiation of pancreatic cancer cell lines by PPARγ ligand troglitazone

Pancreas

Volumn 24, Issue 1, 2002, Pages 1-7

  Kawa, S ^a   Nikaido, T ^a   Unno, H ^a   Usuda, N ^a   Nakayama, K ^a   Kiyosawa, K ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

p21; Pancreatic cancer; PPAR ; Troglitazone

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE; PROTEIN P21; TROGLITAZONE;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; ENZYME ACTIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION;

ADENOCARCINOMA; CELL DIFFERENTIATION; CELL DIVISION; CHROMANS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; LIGANDS; PANCREATIC NEOPLASMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 0036135985     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-200201000-00001     Document Type: Article

References (28)

1. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
2. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid)
3. Inhibitory effect of 22-oxa-1,25-dihydoroxyvitamin D3 on the proliferation of pancreatic cancer cell lines
4. Vitamin D analogues upregulate p21 and p27 during growth inhibition of pancreatic cancer cell lines
5. Arotinoid mofarotene (RO40-8757) up-regulates p21 and p27 during growth inhibition of pancreatic cancer cell lines
6. Effects of troglitazone on the growth and differentiation of hematopoietic cell lines
7. Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p21WAFI/CIPI cyclin-dependent kinase inhibitor
8. Terminal differentiation of human breast cancer through PPARγ
9. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice
10. Ligands for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo
11. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma
12. Differentiation and reversal of malignant changes in colon cancer through PPARγ
13. Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells
14. Peroxisome proliferator-activated receptor γ induces growth arrest and differentiation markers of human colon cancer cells
15. Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells
16. Activators of the nuclear receptor PPARγ enhance colon polyp formation
17. Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCmin/+mice
18. p53 is not inactivated in B6C3FI mouse vascular tumors arising spontaneously or associated with long-term administration of the troglitazone
19. Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing
20. Evaluation of a tetrazolium-based semiautomated colorimeric assay: Assessment of radiosensitivity
21. Posttranscriptional regulation of p21 expression in human breast carcinoma cells
22. Role of apoptosis in copper deficiency-induced pancreatic involution in the rat
23. Terminal differentiation of human liposarcoma cells induced by ligand for peroxisome proliferator γ and the retinoic X receptor
24. Activation of peroxisome proliferator-activated receptor γ by troglitazone inhibits cell growth through the increase of p27(Kipl) in human pancreatic carcinoma cells
25. The E2F transcription factor is a cellular target for the Rb protein
26. Joining the complex: Cyclin-dependent kinase inhibitory proteins and cell cycle
27. Stifled by inhibitors
28. Role of PPARγ in regulating a cascade expression of cyclin-dependent kinase inhibitors, p 18(INK4c) and p21(Wafl/Cipl), during adipogenesis